HU-210

Template:Short description Template:Cs1 config Template:Drugbox HU-210 is a synthetic cannabinoid that was first synthesized in 1988 from (1R,5S)-myrtenol<ref name="Mechoulam et al 1990">Template:Cite journal</ref> by a group led by Raphael Mechoulam at the Hebrew University.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action.<ref name="pmid1317925">Template:Cite journal</ref> HU-210 has a binding affinity of 0.061 nM at CB₁ receptors<ref>Template:Cite journal</ref> compared to 40.7 nM for Δ⁹-THC.<ref>Template:Cite journal</ref> The binding pose of HU-210 to the CB₁ receptor is similar to other synthetic cannabinoids.<ref>Template:Cite journal</ref>

Effects and researchEdit

HU-210, the (–) enantiomer, is an ultrapotent cannabinoid, while its (+) enantiomer HU-211 is not a cannabinoid, but an NMDA antagonist with neuroprotective effects.<ref>Template:Cite journal</ref><ref name="pmid14534855">Template:Cite journal</ref>

HU-210 has an oral LD₅₀ of 5,000 mg/kg in rats and 14,200 mg/kg in rabbits,<ref name="caymanchem 90083m">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and an LD_LO (lowest lethal dose) of 143 mg/kg in humans.<ref name="caymanchem 90083m"/> This is more toxic than Δ⁸-THC; in monkeys and dogs, 9,000 mg/kg of Δ⁸-THC was nonlethal.<ref>Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

ChemistryEdit

HU-210 is the enantiomer of HU-211 (dexanabinol). The original synthesis of HU-210 is based on an acid-catalyzed condensation of (–)-Myrtenol and 1,1-Dimethylheptylresorcinol (3,5-Dihydroxy-1-(1,1-dimethylheptyl)benzol).<ref name="Mechoulam et al 1990"/>

HU-210 synthesis

Legal statusEdit

HU-210 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971,<ref name="UNCPS">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> so the signatory countries to these international drug control treaties are not required by said treaties to control HU-210.

New ZealandEdit

HU-210 is banned in New Zealand as of 8 May 2014.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

United StatesEdit

HU-210 is not explicitly listed in the list of scheduled controlled substances in the USA.<ref name="PART 1308 — SCHEDULES OF CONTROLLED SUBSTANCES - 1308.11 Schedule I">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> A brief profile of HU-210 written and published by the Drug Enforcement Administration (DEA) in 2009, but removed in later years, stated that HU-210 is a Schedule I controlled substance under the Controlled Substances Act due to being similar to THC.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> A version of the document (updated in 2013), now in PDF form, exists on the DEA Office of Diversion Control's website.<ref name=USDOJ>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In that PDF, the DEA reasserts that HU-210 is a Schedule I substance. The DEA currently considers HU-210 a Schedule I controlled substance under the umbrella of ‘tetrahydrocannabinols’ under CSCN 7370.<ref>Template:Cite book</ref>

AlabamaEdit

HU-210 is a Schedule I controlled substance in Alabama.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Template:Quote

FloridaEdit

HU-210 is a Schedule I controlled substance, categorized as a hallucinogen, making it illegal to buy, sell, or possess in the state of Florida without a license.<ref name="Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Template:Cquote

VermontEdit

Effective January 1, 2016, HU-210 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."<ref>Template:Cite book</ref>

ReferencesEdit

Template:Reflist